google-site-verification: googlec7193c3de77668c9.html

Cracking prostate cancer's code: An enzyme's central role in controlling subtypes and improving therapeutic response

[
A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at EPFL, and Eneda Toska at Johns Hopkins University have identified the enzyme KMT2D as a key epigenetic regulator in prostate cancer. Their study published in Cancer Research reveals that KMT2D plays a central role in shaping how prostate tumors grow, survive, and respond to therapy.


Source link

Advertisements
Views: 0

See also  Arsenal & Chelsea top Deloitte money league for women's football

Check Also

One pint, one bold promise: What this beer health claim hides about alcohol's real trade-offs

[ Beer could come with a “surprising health benefit,” according to a new report from …

The Bondi Beach terror attack mobilized a team of volunteer medics. Here’s what we learned

[ A geospatial overview of the attack and response. CHS, Community Health Support; EOC, Emergency …

A brownie, a drink, a drive: Hidden impairment standard sobriety tests completely miss

[ Johns Hopkins Medicine researchers have added to evidence that using cannabis edibles and alcohol …

Leave a Reply

Available for Amazon Prime
Go current digital resources ebook store. cassinox üyelik avantajları.